Form 4: Terns Pharmaceuticals CFO Sells Shares to Cover Tax Obligations and Under Pre-Arranged Trading Plan

Terns Pharmaceuticals' Chief Financial Officer, Mark J. Vignola, sold a total of 17,188 shares of common stock in two transactions to cover tax obligations and under a pre-arranged trading plan.

Summary

• Mark J. Vignola, the Chief Financial Officer of Terns Pharmaceuticals, sold 8,129 shares of common stock on January 2, 2025, at a weighted average price of $5.7232 per share.
• These shares were sold to cover taxes associated with the vesting of a restricted stock unit award.
• The sale was not a discretionary trade by Mr. Vignola.
• On January 6, 2025, Mr. Vignola sold an additional 9,059 shares of common stock at a weighted average price of $5.7953 per share.
• This second sale was executed under a Rule 10b5-1 trading plan adopted on March 18, 2024.
• Following these transactions, Mr. Vignola's direct holdings of Terns Pharmaceuticals common stock decreased to 74,752 shares.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity, with sales executed for tax purposes and under a pre-arranged plan. There is no indication of positive or negative sentiment, it is a neutral event.

Risks

• Sales by company insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are routinely disclosed through SEC filings. The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the pharmaceutical industry such as Gilead Sciences and Amgen.
• These plans allow for pre-scheduled sales of stock to avoid accusations of insider trading.
• The sale of shares to cover tax obligations related to vesting stock options is also a standard practice among executives at companies like Regeneron and Vertex Pharmaceuticals.

Stakeholder Impact

• The sales may have a minor impact on shareholders, but the transactions are routine and do not indicate any change in the company's fundamentals.

Key Dates

Keywords

Terns Pharmaceuticals, insider trading, Form 4, Mark J. Vignola, stock sale, Rule 10b5-1, CFO, share sale, restricted stock unit, tax obligations